Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

• Published in: The New England journal of medicine Vol. 380; no. 4; pp. 347 - 357
• Main Authors: Wiviott, Stephen D, Raz, Itamar, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Silverman, Michael G, Zelniker, Thomas A, Kuder, Julia F, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John P.H, Ruff, Christian T, Gause-Nilsson, Ingrid A.M, Fredriksson, Martin, Johansson, Peter A, Langkilde, Anna-Maria, Sabatine, Marc S
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 24.01.2019
• Subjects: adverse effects; Aged; Animal biology; Antidiabetics; Arteriosclerosis; Benzhydryl Compounds; Benzhydryl Compounds - adverse effects; Benzhydryl Compounds - therapeutic use; Cardiovascular disease; Cardiovascular Diseases; Cardiovascular Diseases - etiology; Cardiovascular Diseases - mortality; Cardiovascular Diseases - prevention & control; Cellular Biology; Cerebral infarction; Clinical Medicine; complications; Congestive heart failure; Death; Diabetes; Diabetes Mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetic ketoacidosis; Drug therapy; End-stage renal disease; epidemiology; etiology; FDA approval; Female; Food and Nutrition; Glomerular filtration rate; Glucosides; Glucosides - adverse effects; Glucosides - therapeutic use; Heart attacks; Heart Failure; Heart Failure - epidemiology; Heart rate; Hospitalization; Hospitalization - statistics & numerical data; Humans; Ischemia; Ketoacidosis; Kidney diseases; Klinisk medicin; Life Sciences; Male; Middle Aged; Mortality; Myocardial infarction; Patients; Pharmaceutical sciences; prevention & control; Safety; Sodium; Sodium-glucose cotransporter; Sodium-Glucose Transporter 2 Inhibitors; Sodium-Glucose Transporter 2 Inhibitors - adverse effects; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; statistics & numerical data; therapeutic use; Type 2
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa1812389

In a randomized trial of patients with type 2 diabetes, treatment with dapagliflozin, an SGLT2 inhibitor that promotes glucosuria, did not result in a higher or lower rate of cardiovascular death, myocardial infarction, or stroke than placebo but did result in a lower rate of hospitalization for heart failure.